Connect with us

Industry News

Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

Avatar

Published

on

default_cannabis_industry_cannamaps

MONTREAL, July 10, 2019 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which will provide pediatric customers with the ability to obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy from different government agencies for the treatment of medical conditions for pediatric patients.The partnership agreement will provide Relevium’s pediatric customers with access to an experienced legal and case management team, who will prepare the case file and seek retroactive and prospective reimbursement for parents of pediatric patients at no cost. The agreement provides Relevium with a unique advantage in terms of its business development strategy and first to market positioning in terms of pediatric applications. Mr. Aurelio Useche, CEO of Relevium stated: “As we prepare to enter the pediatric endo-medicinal market in Canada with an initial ten (10) CannaKids® formulated products, not only are we providing parents with a natural alternative and/or health support mechanism, but now we are able to provide them with the ability to seek reimbursement from governmental agencies without any costs,” Mr. Useche stated further: “We are extremely happy to work with a team of caring legal professionals that can represent our customers in minimizing the financial burden of cannabinoid therapy.”Maitre Robert Astell, President of SOSCannabis.com stated “We are delighted to welcome Relevium into our family of medicinal cannabinoid therapy suppliers. The focus and quest of Relevium in terms of pediatric patients is admirable and we look forward to onboarding parents into our fully-automated registration platform and to provide them with the state-of-the-art case management service in fulfilling their need for economic assistance in providing natural medicine to their children.”Tracy Ryan, CEO of Cannakids® stated: “For years patients have struggled with the high expenses that come along with using cannabis as a medicine. Especially parents to sick children who often lose their jobs due to countless hospital stays and doctor’s appointments. This new opportunity for families is a major step in the right direction. We are elated that more will now have the opportunity to afford this powerful, non-toxic option that we have seen bring unimaginable relief to patients on a global scale.”
About S.O.S Cannabis
SOSCannabis.com is a multi-disciplinary law firm headquartered in Québec, Canada whose objective is to help people that use medical cannabis prescribed by a doctor to seek retroactive and prospective monetary reimbursement through claims made to governmental organizations. SOS Cannabis also provides referral services to a network of medical professionals and medical cannabis suppliers. The company counts with an experienced legal and administrative team to support medical claims with the provincial and federal governments.
About Cannakids®
CannaKids.org is a privately held company that has provided CO2 extracted, lab tested cannabis oil products to thousands of patients over the past 4 years. Using nurse guided assistance, the brand has been synonymous with some of the most recognized patient success stories in the world.
About Relevium Technologies
Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.

Original story can be found at: http://www.globenewswire.com/news-release/2019/07/10/1880887/0/en/Relevium-Signs-Exclusivity-Agreement-With-SOSCannabis-com-for-Reimbursement-for-Pediatric-Patients.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

CV Sciences, Inc. Expands Operations with New Production and Warehousing Facility to Support Worldwide Growth Opportunities

Avatar

Published

on

default_cannabis_industry_cannamaps

Facility Expansion Increases Hemp CBD Oil Production and Warehousing/Fulfillment Capacity by More Than 500 Percent
SAN DIEGO, July 16, 2019 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its industry-dominating brand, PlusCBD™ Oil, today announced the expansion of its operations with a new production and warehouse facility.The 45,500 square foot facility will expand the Company’s capacity for hemp CBD oil production, warehousing and fulfillment by more than 500 percent to meet growing retailer and consumer demand for PlusCBD™ Oil products.  The facility, located in San Diego, is expected to be operational in the fourth quarter of 2019 and will support CV Sciences’ U.S. and international expansion opportunities.“Our recently announced U.S. hemp sourcing initiative combined with this facility and capacity expansion positions CV Sciences for continued rapid domestic growth, while ensuring we are well-positioned to capitalize on the international opportunities we are currently exploring,” said Joseph Dowling, Chief Executive Officer.  “The distribution of PlusCBD™ Oil products into national retailers in the Food, Drug and Mass (FDM) channel is growing significantly, yet we are still in the early stages of growth. Despite more than doubling the number of stores carrying our industry leading products to 4,591 stores in the first six months of this year, we see a significant runway for additional growth, including increasing our domestic and international store count, as well as broadening product SKUs with our retail partners.”On July 10, 2019, CV Sciences announced the commencement of its domestic hemp sourcing initiative, including a commitment to more than 500 acres of U.S.-based hemp production for 2019.  This new supply of U.S. produced hemp-based CBD will be extracted through CV Sciences’ domestic supply chain partners and refined at the Company’s San Diego production facilities, broadening the Company’s global supply chain and raw material supply while reducing transportation and logistics costs.Dowling continued, “CV Sciences is the first hemp CBD company to achieve self-affirmed Generally Recognized as Safe (GRAS) status in accordance with stringent U.S. Food and Drug Administration safety guidelines.  Our relentless commitment to regulatory leadership as well as product safety, quality and efficacy through scientific evidence has established confidence and trust with retailers and consumers.  Expanding our GRAS raw material supply capability builds on our strong foundation to make PlusCBD™ Oil products available to more consumers around the globe.”About CV Sciences, Inc.CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil is the top-selling brand of hemp-based CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.CONTACT INFORMATION:Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/07/16/1883333/0/en/CV-Sciences-Inc-Expands-Operations-with-New-Production-and-Warehousing-Facility-to-Support-Worldwide-Growth-Opportunities.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

MustGrow Biologics Corp. Featured in Exclusive NetworkNewsWire Broadcast

Avatar

Published

on

default_cannabis_industry_cannamaps

NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) — via NetworkNewsAudio – MustGrow Biologics Corp. (CSE: MGRO), an agricultural biotech company developing and commercializing a portfolio of natural biopesticides and bio-fertilizers, today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community.
The interview can be heard at http://nnw.fm/WDud1.MustGrow president and CEO Corey Giasson joins NNW host Stuart Smith in a discussion about the company’s novel, proprietary technology that utilizes organic components refined from the mustard seed to provide high-quality organic solutions for growers facing soil borne diseases and pests such as nematodes in their greenhouses and fields.“We’re an agriculture biologics company that has an innovative technology which uses the mustard seed,” Giasson explains. “We take the mustard seed and extract the natural compounds from that mustard seed, concentrate them, and with them they can be used as a natural bio-fumigate or biopesticide in the food and vegetable industry as well as potentially in the cannabis industry.”Nematodes, or microscopic worms, are the most numerous multicellular animals on earth. A handful of soil will contain thousands of nematodes, many of which are parasites of insects, plants or animals. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients.MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. The global economic impact of soil-borne nematodes is estimated at nearly $100 billion in lost crops per year. The company’s initial product was produced in granular form and sold to growers in the fruit and vegetable space, specifically to strawberry growers, Giasson says.“Our second-generation technology is in liquid form and is more concentrated,” he adds. “We are looking forward to getting the regulatory approval to start selling that into the market.”MustGrow’s potential application for cannabis production shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia, and botrytis (gray mold) that affect the cannabis plant. Giasson notes that “a lot of the funguses that affect the strawberry plant also affect the cannabis plant.”The company’s management team and advisory board is stacked with experts in the agriculture biotech industry and vertical biologics, along with renowned experts in the cannabis space such as Tom Flow, founder of The Flowr Corporation. MustGrow recently announced closing of a non-brokered $1.2 million private placement with those funds already dedicated to developing and commercializing its patented technology, finalizing formulations and conducting field tests on cannabis crops.MustGrow’s biopesticide has U.S. EPA (Environmental Protection Agency) and Canadian PMRA (Pest Management Regulatory Agency) labels as an approved organic solution and is seeking approval to add cannabis as an accepted use.About MustGrowMustGrow is an agricultural biotech company focused on developing and commercializing a portfolio of patented natural bio-pesticides and bio-fertilizers, including its patented signature mustard-derived biologics. Targeting the fruit and vegetable and the cannabis industries, MustGrow has designed a U.S. EPA and Canadian PMRA approved organic solution that uses the mustard seed’s natural defense mechanisms to protect plants from pests and diseases.To learn more, please contact the Company at 1 (306) 717-1128 or visit: www.mustgrow.caAbout NetworkNewsAudioNetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.For more information, visit: www.NetworkNewsAudio.comPlease see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.Forward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.Corporate Communications:NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com 
212.418.1217 Office 
Editor@NetworkWire.com 

Original story can be found at: http://www.globenewswire.com/news-release/2019/07/16/1883316/0/en/MustGrow-Biologics-Corp-Featured-in-Exclusive-NetworkNewsWire-Broadcast.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

CBD Life Sciences Files Initial Reg A+ Offering Statement

Avatar

Published

on

default_cannabis_industry_cannamaps

SCOTTSDALE, AZ, July 16, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CBD Life Sciences Inc. (OTC: CBDL) is pleased to announce that it has filed an offering statement with the United States Securities Exchange Commission (SEC) to raise $10 million under a Regulation A+ securities offering. The net proceeds of this offering will be used to advance the CBD based product lines of its wholly owned subsidiary, LBC Bioscience and to establish a lab for research and development. By utilizing Regulation A+, CBD Life Sciences Inc. will make its securities available to investors who may not otherwise be able purchase nor qualify as accredited. The offering is being prices at $0.10 per share with a minimum allotment $1,000.    
“We are very excited to be moving forward with our Reg A+ offering,” stated Lisa Nelson, President & CEO of CBD Life Science. “We priced the Reg A+ at a premium as we are confident that the current market price does not accurately reflect the true valuation of our company nor the potential that comes with this additional capital,” continued Ms. Nelson. About CBD Life Sciences Inc.CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol ‘CBDL’. The Company’s main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching for additional opportunities within this emerging sector.About LBC Bioscience Inc.  LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesaling  a full line of cannabidiol based organic products including hemp drops, massage oils, pain relief creams, anxiety and sleep  supplements, CDB edibles, anti-aging skin solutions and a full line of CBD infused supplements for your pets. LBC’s products can be viewed and purchased on the company’s website at www.lbcbioscienceinc.com.Contact InformationInvestor RelationsTen Associates LLC11529 N. 120th St.Scottsdale, Arizona85259 USATelephone: 480-326-8577Thomas E. NelsonEmail: tenassociates33@gmail.comForward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.Safe Harbor StatementThis release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Original story can be found at: http://www.globenewswire.com/news-release/2019/07/16/1883256/0/en/CBD-Life-Sciences-Files-Initial-Reg-A-Offering-Statement.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending